E M Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.74 M
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 M
- Revenue Growth 3.09%
- Profit Growth -100.32%
- Ebitda -14.46%
- Net Worth -125.08%
- Total Assets -5.94%
About E M Pharmaceuticals
E M Pharmaceuticals Private Limited (EMPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 April 1992 and has a history of 32 years and ten months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.74 M.
The company currently has active open charges totaling ₹2.40 M.
Ajit Desai and Heena Patel serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24239MH1992PTC066216
-
Company No.
066216
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Apr 1992
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at E M Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajit Desai
|
Director | 16-Aug-2018 | Current |
|
Heena Patel
|
Director | 25-Jun-2015 | Current |
Financial Performance of E M Pharmaceuticals.
E M Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.09% increase. The company also saw a substantial fall in profitability, with a 100.32% decrease in profit. The company's net worth observed a substantial decline by a decrease of 125.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of E M Pharmaceuticals?
In 2021, E M Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sterkem Pharma Private LimitedAjit Desai and Heena Patel are mutual person
Charges (Loans)
₹2.40 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.12 Cr
- Central Bank Of India : 0.10 Cr
- Dena Bank : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Mar 2021 | Hdfc Bank Limited | ₹1.20 M | Open |
| 26 Nov 1998 | Central Bank Of India | ₹1.00 M | Open |
| 16 Apr 1992 | Dena Bank | ₹0.20 M | Open |
How Many Employees Work at E M Pharmaceuticals?
Unlock and access historical data on people associated with E M Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of E M Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped E M Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
